Personalized vaccine plus immune booster after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a personalized vaccine made from your own tumor, combined with a drug that helps your immune system fight cancer cells. The goal is to see if this approach can help prevent your pancreatic cancer from coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove your pancreatic tumor, and the surgeon believes all visible tumor was taken out.
- Your cancer has not spread to distant organs (such as the liver or lungs).
- You are not currently taking other treatments for your pancreatic cancer (like chemotherapy or radiation).
- You are in reasonably good health, able to take care of yourself, and have a life expectancy of at least 6 months.
- You do not have an active autoimmune disease, active infections like hepatitis B or C, or a history of other cancer in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to see if the vaccine can help prevent the cancer from coming back.
This trial combines a new vaccine (XH001) with chemotherapy after surgery for pancreatic cancer. The vaccine aims to train your immune system to fight any remaining cancer cells, potentially lowering the chance of the cancer coming back.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
This trial tests two different vaccines (GVAX and a mKRAS vaccine) given before and after surgery for pancreatic cancer. Both vaccines are combined with immunotherapy drugs to help your immune system fight the cancer. The goal is to see which vaccine works better and is safe for patients whose tumors can be removed.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.